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Levofloxacin-containing triple therapy versus bismuth-
based quadruple therapy as regimens for second line 
anti- Helicobacter pylori 
 
Abstract 
Background: Although the prevalence of Helicobacter pylori infection decreased 
following the hygiene promotion and application of proper anti- H.pylori treatments, 
unfortunately gradual increase is reported in treatment failure; hence, application of a 
proper treatment regimen as a second-line therapy is of great importance. 
Methods: In the current randomized, clinical trial, a total of 120 patients with peptic ulcers 
who failed to respond to treatment were enrolled. In the OLA group, a regimen of 
omeprazole 40 mg/day, levofloxacin 1 g/day, and amoxicillin 2 g/ day was prescribed; 
however, a regimen of omeprazole 40 mg/day, bismuth sub-citrate 480 mg/day, 
furazolidone 400 mg/day, and amoxicillin 2 g/day was administered to the OFAB group. 
Both groups were treated for 2 weeks, and 6 weeks after the treatment, the urea breath test 
(UBT) was performed in the subjects. Collected data were analyzed with SPSS Version 18. 
At the end, 58 patients in group OLA and 57 patients in the OFAB group were analyzed. 
Results: According to the results of the current study, 96.7% of the subjects in the OLA 
and 95% in the OFAB groups completed the treatment course and the eradication rates 
were 86.7% and 78.3% in the OLA and OFAB groups, respectively (P=0.23). Treatment 
side effects were observed in 51.7% and 11.7% of the subjects in the OLA and OFAB 
groups, respectively (P<0.01). 
Conclusion: Both regimens were applicable as the second-line therapy due to insignificant 
difference between the results of the 2 groups; however, OLA regimen was superior to 
OFAB, due to lower side effects. 
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Helicobacter pylori is a Gram-negative bacterium and urease positive is the typical 
characteristic of the species, which can survive in gastric environment and successfully 
able to colonize the gastric antrum (1). Different studies indicated that H. pylori infection 
may be followed by different outcomes such as chronic gastritis, peptic ulcers, functional 
dyspepsia, and gastric cancer (2). In addition, multitude relationships were found between 
H. pylori infection and some extra intestinal diseases such as cardiovascular complications, 
diabetes, pulmonary involvements, hematological and neurological diseases, and glaucoma 
(3, 4). In a large study that covered 410 879 participants from 73 countries, among whom 
the overall prevalence of H. pylori was 44.3% (95%CI: 40.9-47.7) (5). In Iran, the 
prevalence of H. pylori infection has been reported to be at least 36% in Kurdistan and as 
high as 90% in Ardebil. (6).  
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Different factors such as geographical properties, culture, 
and age, as well as socioeconomic factors influence the 
prevalence of H. pylori infection (8).Although the prevalence 
of infection is reduced by the hygiene promotion and 
application of proper anti-H. pylori treatments, unfortunately 
the gradual increase of treatment failure is simultaneously 
reported (9)to such an extent that the successful eradication 
rate of H. pylori dropped from 90% in 1990 to less than 60% 
currently (10). One of the main obstacles to the eradication 
of H. pylori is the antimicrobial resistance of these bacteria, 
particularly against clarithromycin probably caused by its 
indiscriminate administration for upper respiratory tract 
infections  (11, 12). It is already confirmed that H. pylori can 
make efflux pumps over its cell wall for the rapid excretion 
of clarithromycin from bacterial cell and inhibit the 
attachment of clarithromycin to bacterial ribosome (12).The 
frequency of antibiotic resistance in H. pylori is different 
among the countries (13, 14). For example, increased 
resistance to clarithromycin and metronidazole in some 
Asian regions, such as Japan, reduced the potency of triple 
regimens to eradicate H. pylori (14).  
The treatment regimen should mainly focus on 
maintaining successful H. pylori eradication up to 85% and 
prevent the emergence of antibacterial resistance. The PPI 
(proton-pump inhibitors) triple therapy, including 2 
antibiotics of clarithromycin + amoxicillin or metronidazole 
for 14 days is the most commonly administered regimen (14, 
15). A meta-analysis compared the routine triple regimen 
with a bismuth-based quadruple regimen and reported the 
eradication of H. pylori in 80% of the patients who received 
the quadruple regimen and 79% of the ones who received the 
triple regimen, which indicated similar efficiency for the 2 
regimens. Even it seems that the bismuth-based quadruple 
regimen was more useful for the cases who failed to respond 
to the routine triple regimen (16, 17). 
 It seems that by the 20-year experience in the treatment 
of H. pylori infection, there is a long way ahead for 
researchers to find the ideal regimen. Different clinical trials 
as well as meta-analyses indicated that PPIs + 2 antibiotics 
were the commonest first-line therapy to eradicate H. pylori. 
This triple regimen fails to treat 20% of the patients and the 
rate even may be higher in adults. It seems that resistance to 
clarithromycin plays a significant role in the failure of 
treatment (18) regarding significant drug resistance and 
treatment failure in H. pylori infection, the study of various 
therapeutic regimens in the treatment of this infection has a 
special status. Nevertheless, the current study aimed at 
comparing 2 second-line therapies for the eradication of H. 
pylori in patients with peptic ulcers who previously failed to 
response the triple regimen as the first-line therapy. 
 
 
Methods 
The current randomized controlled trial study was 
conducted on patients with peptic ulcer and failure to 
respond to the first-line therapy for H. pylori eradication who 
referred to Shahid Sayyad Shirazi Teaching Hospital in 
Gorgan, Iran.  The study lasted from October 2016 to 
November 2017. After entering the study, each patient was 
given a number from 1 to 120. Each patient received a 
number (in a draw) for each number; there was a drug pack 
(the packages had the same shape) in the pharmacy. Half of 
the packets were OLA treatment regimen and the other half 
were OFAB-regimen. After the completion of the study, it 
was determined which drug was used by each patient. Then, 
a questionnaire including age, gender, medication, and 
clinical records was completed for each subject.  
A total of 120 patients with peptic ulcer, caused by H. 
pylori infection, confirmed by histological examinations of 
biopsy specimens endoscopically taken from upper 
gastrointestinal (GI) tract with positive urea breath test 
(UBT) 6 weeks after completing a 2-week treatment course 
of a triple regimen including omeprazole 40 mg/day, 
clarithromycin 1 g/day, and amoxicillin 2 g/day, as the first-
line therapy, were enrolled into the study. Subjects were 
allocated into 2 study groups using the random sampling 
method.  (See fig 1: consort flowchart) In the OLA group, a 
second-line therapy for H. pylori eradication was 
administered to the subjects with a triple regimen including 
omeprazole 40 mg/day, levofloxacin 1 g/day, and 
amoxicillin 2 g/day for 2 weeks. In the OFAB group, also a 
second-line therapy for the eradication of H. pylori with a 
quadruple regimen was prescribed including omeprazole 40 
mg/day, bismuth sub-citrate 480 mg/day, furazolidone 400 
mg/day, and amoxicillin 2 g/day for 2 weeks. Six weeks after 
the completion of treatment course, UBT was performed and 
the level of eradication and treatment outcomes were 
compared between the groups.  
Collected data were analyzed based on the study 
objectives. The inclusion criteria were as follows: having 
peptic ulcer confirmed by endoscopy, receiving a complete 
course of first-line therapy, and resistance and failure to 
 Caspian J Intern Med 2019; 10(2):211-216  
Treatment Regimens for the Eradication of Helicobacter pylori as a Second-line Therapy                                   213 
respond to the first-line therapy for H. pylori eradication; 
while the exclusion criterion was the irregular consumption 
of antibiotics due to severe side effects. 
 
     
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 1: Consort flowchart (exclusion criterion was the 
irregular consumption of antibiotics due to severe side 
effects) 
 
Data analysis: Collected data were codified and analyzed 
with SPSS Version 18. To express data, the frequency, 
percentage as well as mean and standard deviation (SD) were 
used. To compare age and gender distribution between the 
groups, the chi-square test and one-way analysis of variance 
(ANOVA) were used. To compare the eradication rate of H. 
pylori and results of UBT between the groups, chi-square 
test was conducted. Tables and figures were constructed to 
show the distribution of data. Also, p<0.05 was considered 
as the level of significance for all tests. 
The protocol of the study was approved by the Research 
Ethics Committee of the local university and the required 
permission was given by the authorities of the hospital under 
study. The researcher introduced himself to the study 
subjects and explained the objectives of the study to them. 
Then, the written informed consent was signed by the study 
participants. The subjects were assured about the 
confidentiality of data at the end of the study. The 
participants were free to withdraw from the study at any 
stage. All practices and procedures performed in the current 
study had no mental or physical damage to the subjects and 
were designed based on the Code of Research Ethics 
developed in Golestan University of Medical Sciences, 
Gorgan, Iran. Due to the need for definitive drug therapy in 
the current study, drugs were provided by the patients, but 
the UBT was performed free of charge. Data were published 
anonymous. The research project was registered in the 
Iranian Registry of Clinical Trials (code no. 
IRCT2015123025770N1). 
 
 
Results 
The mean±SD age of the study participants was 
46.26±14.36 years; it was 45.7±14.7 years in the OLA and 
46.8±14.1 years in the OFAB groups. No significant 
difference was observed between the groups regarding the 
mean age, based on ANOVA (P=0.68). 
In addition, 68 subjects (56.66%) of the total population 
were males and 52 (43.34%) females. The groups were 
compared based on the gender distribution and results of chi-
square test showed no significant differences between the 
groups in this regard (P = 0.71). In the current study, 58 
(96.7%) subjects in the OLA group and 57 (95%) in the 
OFAB group completed the treatment course and the rest 
was eliminated due to poor medical compliance and lack of 
interest; there was also no significant difference between the 
groups regarding the number of drop outs. 
The level of response to treatment was assessed in the 
groups and by the end of the study, totally 99 (82.5%) 
subjects responded to treatment. The analysis of frequency 
distribution in both groups showed positive response to 
treatment in 52 (86.7%) subjects in the OLA and 47 (78.3%) 
subjects in the OFAB groups. Results of chi-square test 
showed no significant difference between the groups 
regarding the rate of response to treatment (P=0.23). 
Since the mean age of the study population was 46 years, 
the participants were allocated into 2 groups of >46 years as 
old age and <46 years as the middle age groups and the level 
of response to treatment was also assessed based on gender 
and age (table 1). 
The level of response to treatment is shown in table 1 
based on the age and gender and results showed no 
significant difference between the groups. 
In addition, results indicated the incidence of side effects 
in 38 (31.7%) out of 120 subjects in the current study. For 
better explanation, drug side effects were observed in 31 
(51.7%) subjects in OFAB and 7 (11.7%) subjects in OLA 
groups; results of the chi-square test showed a significant 
difference between the groups in this regard (p<0.01) (table 
2). 
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Table 1. Medical data of the study groups 
Group Response to 
Treatment 
OLA 
% (N) 
OFAB 
% (N) 
Pvalue 
Male  Successful 90.9 (30) 82.9(29) 0.33 
Failed 9.8 (3) 17.1 (6) 
Female  Successful 81.5 (22) 72 (18) 0.42 
Failed 18.5 (5) 28 (5) 
<46 
years 
Successful 90.3 (28) 75 (21) 0.12 
Failed 9.7 (3) 25 (7) 
>46 
years 
Successful 82.8 (24) 81.2(26) 0.88 
Failed 17.2 (5) 18.8 (6) 
OLA: Omeprazole, Levofloxacin, Amoxicillin 
OFAB: Omeprazole, Bismuth Sub-Citrate, Furazolidone, Amoxicillin 
 
Table 2. Comparison of the level of side effects between 
the study groups 
 OLA OFAB P-value 
N % N % 
Nausea and vomiting  5 8.3 16 26.6 P<0.01 
Abdominal pain 1 1.6 10 16.6 P<0.01 
Diarrhea  0 0 4 6.6 P<0.01 
Itching rashes 1 1.6 1 1.6 NS 
     NS: not significant 
 
Discussion 
 In the current study, 58 (96.7%) subjects in the OLA 
group and 57 (95%) in the OFAB group completed the 
treatment course and the rest were eliminated due to poor 
medical compliance and lack of interest; there was also no 
significant difference between the groups regarding the 
number of drop outs. There is no exact ideal regimen as the 
first-line therapy for the eradication of H. pylori, and 
recommendation in this regard varies based on the antibiotic 
resistance pattern in each geographical region. For example, 
the resistance to clarithromycin varies from 18.9% in Asia to 
29.3% in America and 11.1% in Europe (19). Recent reports 
have indicated the reduced efficiency of triple regimens on 
the eradication of H. pylori infection due to the increased 
resistance to clarithromycin and metronidazole caused by 
indiscriminate administration of these antibiotics in the 
Asian countries (20). A study in Iran reported the frequency 
to resistance to metronidazole and tetracycline as 55.6% and 
38.1%, respectively; while, it was 7.3%, 7.3%, and 4.5% 
respectively for clarithromycin, amoxicillin, and 
furazolidone (21). In a study by Mokhtare et al., in Iran on 
48 patients who failed to respond to a furazolidone-based 
regimen, a quadruple regimen including pantoprazole 40 
mg/12 hours, amoxicillin 1 g/12 hours, bismuth sub-citrate 
240 mg/12 hours, and clarithromycin 500 mg/12 hours was 
administered for 10 consecutive days and the subjects 
underwent UBT 8 weeks after the completion of treatment 
course and eradication of H. pylori was reported in 88.4% of 
the subjects (confidence interval (CI)95%: 74.91-96.11) 
(22). Recent clinical guidelines have recommended the 
application of bismuth-based quadruple regimens for 7 to 10 
days as a second-line therapy to eradicate H. pylori (23). 
However, more recent studies have recommended increasing 
the treatment course to 14 days due to the significant 
differences between the results of 7- or 10-day and 14-day 
treatment courses (24). 
 Valid recommendations on the treatment of H. pylori 
infection in patients failing first-line therapy are as below: 
After failure of PPI-clarithromycin-amoxicillin triple 
therapy, a bismuth-containing quadruple therapy or a 
fluoroquinolone-containing triple or quadruple therapy are 
recommended as a second-line treatment. And after the 
failure of a non-bismuth quadruple therapy, either a bismuth 
quadruple therapy or a fluoroquinolone-containing triple or 
quadruple therapy are recommended and after failure of 
bismuth-containing quadruple therapy, a fluoroquinolone-
containing triple or quadruple therapy may be recommended. 
In cases of high quinolone resistance, the combination of 
bismuth with other antibiotics, or rifabutin, may be an option 
(25). The current study compared the effect of omeprazole, 
levofloxacin, amoxicillin with omeprazole, bismuth sub-
citrate, furazolidone and amoxicillin 14-day regimen as the 
second-line therapy to eradicate H. pylori. The eradication 
rate was acceptable in both groups of the current study and 
the difference between the groups was insignificant (86.7% 
in OLA vs. 78.3% in OFAB). 
Gu et al in China conducted a study on 138 patients 10 
days after failure to respond to the treatment regimen. The 
patients received a 14-day quadruple regimen including 
pantoprazole, bismuth sub-citrate, and furazolidone plus 
ofloxacin or levofloxacin. The eradication level was 81.4% 
in the ofloxacin group based on the intention-to-treat 
analysis, while it was 87.7% in the per-protocol analysis, 
which both were significantly higher than those of the 
levofloxacin group (66.2% and 72.6%, respectively). They 
reported no side effects in the study groups (26). Xie et al., 
(26) in a study in China evaluated 720 patients with H. pylori 
infection and duodenal ulcer. The subjects were randomly 
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allocated into each of the following groups:Groups 1 and 3 
received rabeprazole 10 mg, amoxicillin 1000 mg, and 
furazolidone 100 mg twice a day for 7 and 10 days, 
respectively; groups 2 and 4 received rabeprazole 10 mg, 
bismuth sub-citrate 220 mg, amoxicillin 1000 mg, and 
furazolidone 100 mg twice a day for 7 and 10 days, 
respectively. The primary consequences of H. pylori 
eradication were assessed 4 weeks after the completion of 
the treatment course based on the intention-to-treat and per-
protocol analyses, and the secondary consequences evolved 
the evaluation of changes in sign and symptoms 4 weeks 
after the completion of the treatment course. Drug side 
effects were reported in some of the subjects. Out of the total 
population, 666 patients completed the treatment course and 
were reexamined by UBT. The level of intention-to-treat in 
the study groups (1, 2, 3, and 4) was as follows 74.44%, 
82.78%, 78.89%, and 86.11%, respectively. The rate of H. 
pylori eradication was significantly higher in group 4, 
compared with that of the group 1. Analysis of the results 
showed the H. pylori eradication ratein 4 groups respectively 
as 81.21%, 89.22%, 85.54%, and 92.26%. The side effects 
including dizziness, vomiting, diarrhea, nausea, rash, itching, 
and weakness and lethargy were self-limited (24). According 
to the results of the current study, there was a direct 
relationship between better response to treatment and longer 
treatment courses with more drug items. 
Liang et al. (27) in China studied 61 patients with H. 
pylori infection who failed to respond a 7-day standard triple 
regimen. They were given a triple regimen including 
levofloxacin 500 mg/day, amoxicillin 1 g/12 hours, and 
esomeprazole 40 mg/12 hours and the eradication rate was 
reported 77% based on the intention-to-treat analysis and 
81% based on the per-protocol analysis; their results were 
consistent with those of the current study. The rate of side 
effects and drug tolerance were 6.6% and 95.1%, 
respectively (28); the tolerance rate was similar to that of the 
current study. Accordingly, 96.7% of OLA group subjects 
and 95% of OFAB patients completed the treatment course. 
Although the rate of side effects was high in the current 
study and about half of the subjects in the OFAB and 11.7% 
in the OLA groups experienced side effects, most of the 
subjects completed the treatment course (28). The results of 
similar studies showed the increase of side effects following 
the application of furazolidone-based regimens; 51.7% of the 
subjects in OFAB group showed side effects, which is in 
agreement with findings about furazolidone. The limitation 
of this study is the need for large amounts of tablets to be 
taken by patients and also the need for referral patients to 
follow the eradication of H. pylori. 
In conclusion, although no significant difference was 
observed between the groups regarding the H. pylori eradication 
rate, higher side efficiency of furazolidone-based regimens is 
a remarkable point in the current study. Hence, the application 
of furazolidone-free regimen as the second-line therapies is 
recommended in the current study; on the other hand, since 
Levofloxacin showed satisfactory results in the current as 
well as similar studies lower side effects of levofloxacin than 
furazolidone and bismuth suggests the involvement of this 
antibiotic in the H. pylori eradication regimens. 
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